scholarly journals Systemic sclerosis as prototypic disease with high levels of functional antibodies against angiotensin II type-1 and endothelin-1 type A receptor strongly predicting prognosis

2010 ◽  
Vol 69 (Suppl 2) ◽  
pp. A5-A5 ◽  
Author(s):  
G Riemekasten ◽  
A Philippe ◽  
I Lukitsch ◽  
T Slowinski ◽  
M Nather
Keyword(s):  
Systemic Sclerosis ◽  
Angiotensin Ii ◽  
Type A ◽  
Endothelin 1 ◽  
Functional Antibodies

Autoantibodies against Endothelin 1 Type A Receptor Are Strong Predictors of Digital Ulcers in Systemic Sclerosis

2015 ◽  
Vol 42 (10) ◽  
pp. 1801-1807 ◽  
Author(s):  
Jérôme Avouac ◽  
Gabriela Riemekasten ◽  
Christophe Meune ◽  
Barbara Ruiz ◽  
André Kahan ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Type A ◽  
Digital Ulcers ◽  
Clinical Predictors ◽  
Endothelin 1 ◽  
History Of ◽  
Angiogenic Markers ◽  
Cox Analysis ◽  
Or History

Objective.To determine the predictive value of functional autoantibodies against vascular receptors for the development of ischemic digital ulcers (DU) in patients with systemic sclerosis (SSc).Methods.Angiotensin II Type 1 receptor (AT1R) and endothelin 1 Type A receptor (ETAR) autoantibodies were measured at baseline in a prospective cohort of 90 patients with SSc together with 5 validated angiogenic markers. The primary outcome was the occurrence of at least 1 new ischemic DU during the 5-year followup.Results.Twenty-four patients developed at least 1 new DU during the followup period. Univariate Cox analysis revealed that concentrations above the median value of anti-AT1R and anti-ETAR antibodies were predictive of the occurrence of ischemic DU (HR 2.85, 95% CI 1.19–6.84 and HR 3.39, 95% CI 1.35–8.50, respectively). A first multivariate Cox analysis including functional autoantibodies and clinical predictors of new DU confirmed anti-ETAR autoantibodies as independent predictors of the occurrence of new ischemic DU (HR 3.15, 95% CI 1.22–8.13) together with a history of DU at baseline. In a second model implemented with angiogenic markers, anti-ETAR autoantibodies remained an independent predictor of the occurrence of new ischemic DU (HR 9.59, 95% CI 1.75–52.64) together with the presence at baseline of active DU or history of DU.Conclusion.Anti-ETAR autoantibodies can be used together with the presence of current or past DU to identify patients with SSc who are at risk for the development of subsequent DU. These autoantibodies may allow for earlier management and therapeutic intervention.

Non-HLA Antibodies: Angiotensin II Type 1 Receptor (Anti-AT1R) and Endothelin-1 Type A Receptor (Anti-ETAR) Are Associated With Renal Allograft Injury and Graft Loss

2014 ◽  
Vol 46 (8) ◽  
pp. 2618-2621 ◽  
Author(s):  
M. Banasik ◽  
M. Boratyńska ◽  
K. Kościelska-Kasprzak ◽  
D. Kamińska ◽  
S. Zmonarski ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Renal Allograft ◽  
Graft Loss ◽  
Type A ◽  
Hla Antibodies ◽  
Endothelin 1

Functional autoantibodies against Endothelin-1 receptor type A and Angiotensin II receptor type 1 in patients with preeclampsia

2018 ◽  
Vol 14 ◽  
pp. 189-194 ◽  
Author(s):  
Sara Buttrup Larsen ◽  
Gerd Wallukat ◽  
Ingolf Schimke ◽  
Anna Sandager ◽  
Therese Tvilum Christensen ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Type A ◽  
Receptor Type ◽  
Angiotensin Ii Receptor ◽  
Endothelin 1

Image mean square displacement to study the lateral mobility of Angiotensin II type 1 and Endothelin 1 type A receptors on living cells

2020 ◽  
Vol 83 (4) ◽  
pp. 381-392
Author(s):  
Nadir Planes ◽  
Patrick P.M.L. Vanderheyden ◽  
Enrico Gratton ◽  
Catherina Caballero‐George
Keyword(s):  
Angiotensin Ii ◽  
Mean Square Displacement ◽  
Type A ◽  
Living Cells ◽  
Mean Square ◽  
Lateral Mobility ◽  
Endothelin 1

scholarly journals Antibodies against Angiotensin II Type 1 and Endothelin 1 Type A Receptors in Cardiovascular Pathologies

2022 ◽  
Vol 23 (2) ◽  
pp. 927
Author(s):  
Giovanni Civieri ◽  
Laura Iop ◽  
Francesco Tona
Keyword(s):  
Angiotensin Ii ◽  
Type A ◽  
Receptor Type ◽  
Current Evidence ◽  
Circulatory Support ◽  
Angiotensin Ii Receptor ◽  
Endothelin 1 ◽  
Coronary Syndromes ◽  
Cardiovascular Pathologies

Angiotensin II receptor type 1 (AT1R) and endothelin-1 receptor type A (ETAR) are G-protein-coupled receptors (GPCRs) expressed on the surface of a great variety of cells: immune cells, vascular smooth cells, endothelial cells, and fibroblasts express ETAR and AT1R, which are activated by endothelin 1 (ET1) and angiotensin II (AngII), respectively. Certain autoantibodies are specific for these receptors and can regulate their function, thus being known as functional autoantibodies. The function of these antibodies is similar to that of natural ligands, and it involves not only vasoconstriction, but also the secretion of proinflammatory cytokines (such as interleukin-6 (IL6), IL8 and TNF-α), collagen production by fibroblasts, and reactive oxygen species (ROS) release by fibroblasts and neutrophils. The role of autoantibodies against AT1R and ETAR (AT1R-AAs and ETAR-AAs, respectively) is well described in the pathogenesis of many medical conditions (e.g., systemic sclerosis (SSc) and SSc-associated pulmonary hypertension, cystic fibrosis, and allograft dysfunction), but their implications in cardiovascular diseases are still unclear. This review summarizes the current evidence regarding the effects of AT1R-AAs and ETAR-AAs in cardiovascular pathologies, highlighting their roles in heart transplantation and mechanical circulatory support, preeclampsia, and acute coronary syndromes.

Sign in / Sign up

Export Citation Format

Share Document